Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ocaliva In NASH Manageable With Indication-Based Pricing, ICER Roundtable Suggests

Jul 29 2016

• By Cathy Kelly

Related Content

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

Jul 19 2016

NASH Drug Cost Concerns On Level With HCV Treatments For Payers

Apr 20 2016

'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim

Jun 06 2016

Related Companies

Intercept Pharmaceuticals, Inc.

Express Scripts Holding Company

Additional Topics

United States Market Access Pricing Strategies Commercial BioPharmaceutical

More from Market Access

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window